[CAS NO. 1821280-29-8] SBI-0640756
PRODUCTS SPECIFICATIONS [1821280-29-8]
DESCRIPTION [1821280-29-8]
Overview
| MDL | MFCD30343858 |
|---|---|
| Molecular Weight | 404.82 |
| Molecular Formula | C23H14ClFN2O2 |
| SMILES | O=C1C(C(/C=C/C2=CC(F)=CN=C2)=O)=C(C3=CC=CC=C3)C4=C(C=CC(Cl)=C4)N1 |
Summary
SBI-0640756 (SBI-756) is an inhibitor of eIF4G1 and disrupts the eIF4F complex.
IC50 & Target
eIF4G1 [1]
In Vitro
SBI-0640756 (SBI-756) is a water soluble inhibitor of eIF4G1. SBI-0640756 (SBI-756) (0-1 μM) disrupts eIF4F complex in parent and BRAFi-resistant melanoma. SBI-0640756 (SBI-756) shows inhibitory effect on human melanoma lines, and also suppresses AKT, NF-κB and AKT/mTORC1 activity [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SBI-0640756 (SBI-756) (0.5 mg/kg, i.p.) delays tumor onset and reduces tumor incidence by 50% in Nras Q61K /Ink4a –/– genetic model. SBI-0640756 (SBI-756) (1 mg/kg, 2 times per week, i.p.) in combination with BRAF inhibitor potently suppresses growth of established tumors and does not resume tumor growth in immunodeficient mice bearing A375 tumors [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 26 mg/mL ( 64.23 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4702 mL | 12.3512 mL | 24.7023 mL |
| 5 mM | 0.4940 mL | 2.4702 mL | 4.9405 mL |
| 10 mM | 0.2470 mL | 1.2351 mL | 2.4702 mL |